Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab)
M25-056
Phase 2 small_molecule active
Quick answer
Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab) for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Rheumatoid Arthritis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active